Biological Activity
Potent JAK inhibitor (IC50 values are 1, 20, and 112 nM for JAK3, JAK2 and JAK1 respectively). Orally active immunosuppressant; exhibits efficacy in rodent rheumatoid arthritis models.
Licensing Information
Sold for research purposes under agreement from Pfizer Inc.
External Portal Information
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of CP 690550 (Tofacitinib) is reviewed on the chemical probes website.
Compound Libraries
CP 690550 citrate is also offered as part of the Tocriscreen Plus and Tocriscreen Kinase Inhibitor Toolbox II. Find out more about compound libraries available from Tocris.
Technical Data
| M. Wt | 504.49 |
| Formula | C16H20N6O.C6H8O7 |
| Storage | Store at +4°C |
| Purity | ≥99% (HPLC) |
| CAS Number | 540737-29-9 |
| PubChem ID | 10174505 |
| InChI Key | SYIKUFDOYJFGBQ-YLAFAASESA-N |
| Smiles | C[C@H]1[C@@H](N(C2=NC=NC3=C2C=CN3)C)CN(C(CC#N)=O)CC1.OC(CC(O)=O)(C(O)=O)CC(O)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 50.45 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 504.49. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.98 mL | 9.91 mL | 19.82 mL |
| 5 mM | 0.4 mL | 1.98 mL | 3.96 mL |
| 10 mM | 0.2 mL | 0.99 mL | 1.98 mL |
| 50 mM | 0.04 mL | 0.2 mL | 0.4 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the products' biological activity.
Jiang et al (2008) Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J.Med.Chem. 51 8012 PMID: 19053756
Flanagan et al (2010) Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J.Med.Chem. 53 8468 PMID: 21105711
Dowty et al (2013) Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J.Pharmacol.Exp.Ther. 348 165 PMID: 24218541
Keywords: CP 690550 citrate, supplier, CP690550, immunosuppressants, autoimmune, antirheumatics, rheumatoid, arthritis, pfizer, JAK, janus, kinase, JAK1, JAK2, JAK3, inhibitors, inhibits, Tofacitinib, Tofacitinib, citrate, JAK, Kinase, JAK, Kinase, Tocris Bioscience
